Close Menu

Bio-Rad

The firm saw low-single digit growth across its business segments in the quarter as well as in the full year. 

The technology uses single-cell droplet digital PCR to analyze maternal blood cell populations that have been enriched for fetal cells by MACS.

On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.

News items from the in vitro diagnostics industry for the week of Dec. 16, 2019.

The firm saw modest growth across both of its business segments and double-digit growth in its droplet digital PCR product line.

The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.

The study compared a variety of serological tests for visceral leishmaniasis that are available in Brazil, a hotspot for the parasitic disease.

GenMark Diagnostics received clearance for a third BCID panel that the firm said paves the way for a customizable approach to sepsis MDx.

Bio-Rad also disclosed during an earnings call that it acquired an undisclosed company that will expand its genomic reagents product portfolio.

Pages